Article ID Journal Published Year Pages File Type
10218426 Autoimmunity Reviews 2018 11 Pages PDF
Abstract
In conclusion, DOACs are not effective in all APS patients and should not be used routinely in these patients. Randomized controlled trials assessing clinical efficacy and safety as primary endpoints are underway. In the meantime, a registry of APS patients on DOACs could be proposed to establish in which APS subgroups DOACs would be a safe alternative to warfarin.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , , , , ,